Dr. Vagner's research expertise is in the area of design and development of compounds for in vivo pharmacologic applications and drug discovery. He has a background in organic and medicinal chemistry, with specific training in solid phase synthesis and small molecule drug discovery. This 25+ years of expertise also includes structural analysis and design of de novo ligands for various biological targets including a recent focus on multivalent ligand sand drug-ligand conjugates. Dr. Vagner's research career began in the pharmaceutical industry (Sanofi, Novo Nordisk, and SIDCCO) where he specialized in combinatorial chemistry and solid phase synthesis of small molecule libraries. During his time in the industry, he supervised teams of workers who successfully accomplished the synthesis of more than ten large libraries (with 10,000+ compounds each). During the last decade, as a director of the Ligand Discovery Laboratory at the University of Arizona BIO5 Institute, Dr. Vagner was responsible for design, synthesis, purification, characterization of compound libraries for multiple biological targets and their primary screening. Their center is based on collaboration attitude rather than as a core synthetic facility. His role in projects fluctuates from consultant to PI commitment that depends on a structure of assignment.
Currently, I am leading the Ligand Discovery Lab (LDL) at Bio5, University of Arizona. The current research projects deal with the development of ligands, inhibitors, and diagnostic probes in collaboration with the UACC, UNMCC, TGen, Department of Radiology and Department of Biochemistry.
- Solid-phase synthesis (small organic compounds, biopolymers)
- High throughput synthesis (96-well plates)
- One-bead-one-compound (OBOC) library synthesis
- Rational design of small molecule ligands, multimeric ligands, peptidomimetics
- Lanthanide-based time-resolved fluorometry in vivo binding assay
- In vivo cell-adhesion-to-bead assay for OBOC library
- HT synthesis of labeled probes (fluorescent, DOTA-Eu)
- Logistics and QC
- Vagner, J., Barany, G., Lam, K.S., Krchnak, V., Sepetov, N.F., Ostrem, J.A., Strop, P., and Lebl, M., Enzyme-mediated spatial segregation on individual polymeric support beads: application to generation and screening of encoded combinatorial libraries. Proceedings of the National Acadademy of Science of the U.S.A., 93, 8194-8199 (1996).
- Cowell, S.M.; Gu, X.; Vagner, J.; Hruby, V.J. Intelligent design in combinatorial chemistry: use of designed peptide libraries to explore secondary and tertiary structures in peptides and proteins. Methods in Enzymology, 369 (Combinatorial Chemistry, Part B), 288-297 (2003).
- Handl, H.L.; Vagner, J.; Han, H.; Mash, E.; Hruby, V.J.; Gillies, R.J. Hitting multiple targets with multimeric ligands. Expert Opinion on Therapeutic Targets, 8, 565-586 (2004).
- Vagner, J., Handl, H., Gillies, R.J., Hruby, V.J. Novel strategy based on multimeric ligands for drug delivery and imaging: homooligomers of a-MSH. Bioorganic & Medicinal Chemistry Lett. ,14, 211-215 (2004).
- Handl, H.L., Vagner, J., Yamamura H.I., Hruby, V.J., Gillies, R.J. Lanthanide-based time-resolved fluorescence of in cyto ligand-receptor interactions. Analytical Biochemistry, 330, 242-250 (2004).
- Vagner, J., Handl, H.L., Monguchi, Y., Jana, U., Begay, L., Mash, E. A., Hruby, V.J., Gillies, R.J. Rigid linkers for bioactive peptides. Bioconjugate Chemistry, 17,1545-1550 (2006).
- Mayorov, A.V. Cai, M. Palmer, E.S., Dedek, M.M., Cain, J.P., Van Scoy, A.P., Tan, B. Vagner, J., Trivedi, D., Hruby, V.J., Structure-Activity Relationships of Cyclic Lactam Analogues of a-MSH. Targeting the Human Melanocortin-3 Receptor.Journal of Medicinal Chemistry 51, 187-195 (2008).
- Vagner J., Xu L., Handl H.L., Josan J.S., Morse D.L., Mash E.A., Gillies R.J., and Hruby V.J., Heterobivalent Ligands Crosslink Multiple Cell-Surface Receptors: The Human Melanocortin-4 and d-Opioid Receptors. Angewandte Chemie Intl. Ed. 47, 1685-1688 (2008).
- Black, K.C., Kirkpatrick, N.D., Troutman, T.S., Xu, L., Vagner, J., Gillies, R.J., Barton, J.K., Utzinger, U., Romanowski, M. Gold nanorods targeted to delta opioid receptor: plasmon-resonant contrast and photothermal agents. Molecular Imaging 7, 50-57 (2008).
- Vagner, J., Qu, H., Hruby, V.J. Peptidomimetics, a synthetic tool of drug discovery. Current Opinion in Chemical Biology 12(3), 292-296 (2008).
The LDL proram relies on an existing information flow from TGen, and collaborations with other groups:
2006-Present Member, Advanced Research Institute for Biomedical Imaging, University of Arizona, AZ
2005-Present Associate Research Professor, Bio5, University of Arizona, AZ
2005-Present Director of The Ligand Discovery Laboratory, Bio5, University of Arizona, AZ
2002-2005 Assistant Research Professor, Bio5, University of Arizona, AZ
1998-2001 Synthetic Organic Chemist/Principal Scientist, SIDDCO, Tucson, AZ
1995-1998 Research Chemist, Novo Nordisk A/S, Copenhagen, Denmark
1992-1995 Postdoctoral Fellow, Department of Chemistry, University of Minnesota, MN and Selectide (now Sanofi), Tucson, AZ
1990-1992 Research Chemist, Institute of Sera and Vaccines, Prague, Czech Republic
1986-1990 Research Chemist, Leciva Pharmaceuticals, Prague, Czech Republic
The American Peptide Society
The Society of Combinatorial Sciences